newsfilter
← Latest News
GlobeNewswire·

Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates

Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with topline data expected in 2026Cash position of approximately $82 million as of September 30, 2024 with